What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia‐Inducible Factor‐Prolyl Hydroxylase Inhibitors May Change Iron Management in End‐Stage Renal Disease. Issue 1 (4th October 2016)